SCHEMBL3565704

SCHEMBL3565704

CS(=O)(=O)Nc1cccc(-c2cccc(-c3nc(-c4ccc(C(F)(F)F)cc4)cc(C(F)(F)F)n3)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.70
PFKFB3 Q16875 1/20 0.50
SYK P43405 2/20 0.49
ERAP1 Q9NZ08 1/20 0.49
PTGS2 P35354 2/20 0.48
NPY5R Q15761 1/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 2/20 0.47
TP53 P04637 2/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 2/20 0.47
KMT2A Q03164 2/20 0.47
HSD17B10 Q99714 2/20 0.47
S1PR4 O95977 1/20 0.47
POLB P06746 1/20 0.47
S1PR1 P21453 1/20 0.47
SDHB P21912 1/20 0.47
STAT3 P40763 1/20 0.47
STAT1 P42224 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567515 0.89 KIF11 (0.53) KIF11PFKFB3ERAP1
SCHEMBL3564009 0.88 NTRK1 (0.57) KIF11PFKFB3SYKERAP1PTGS2
SCHEMBL3568019 0.84 SDHB (0.54) PTGS2MEN1LMNATP53HPGD
SCHEMBL4662603 0.83 KIF11 (1.00) KIF11PFKFB3SYKERAP1NPY5R
SCHEMBL3556992 0.79 MEN1 (0.45) MEN1LMNATP53HPGDMAPK1
SCHEMBL3561893 0.79
SCHEMBL3568722 0.79 PTGES2 (0.48) KIF11SYKMEN1LMNATP53
SCHEMBL3562431 0.79 PFKFB3 (0.47) PFKFB3MEN1LMNATP53HPGD
SCHEMBL27743814 0.78 POLB (0.55) PTGS2MEN1LMNATP53HPGD
SCHEMBL3559328 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KIF11 3845/4885PFKFB3 1222/4885SYK 3521/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KIF11 3339/4885PFKFB3 556/4885SYK 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.